CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing conditionally activated, masked biologics localized to the tumor microenvironment [3] - The company utilizes its PROBODY® therapeutic platform to create safer and more effective cancer therapies [3] - CytomX's pipeline includes therapeutic candidates such as CX-2051 and CX-801, with CX-2051 being a masked, conditionally activated ADC targeting epithelial cell adhesion molecule (EpCAM) [3] Financial Results Announcement - CytomX will report its first quarter financial results on May 12, 2025, before the U.S. markets open [1] - A conference call and webcast will follow the announcement at 8:00 a.m. ET / 5:00 a.m. PT [1] Strategic Collaborations - The company has established collaborations with major oncology leaders including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3]